Bortezomib specifically is a first-in-class PI (Proteasome Inhibitor). The proteasome helps in order to control the level of many regulatory proteins that exist in cell replication as well as survival. The bortezomib 3.5 mg injection price is quite reasonable. It is approved for the treatment of Relapsed and refractory multiple myeloma. Bortezomib is administered as a three to five-second IV push. It can be injected directly into a peripheral line, central line catheter, or an infusion port after the standard saline flush to ensure administration of the complete dose